Company Filing History:
Years Active: 2016
Title: Nadja Banziger: Innovator in Medical Biotechnology
Introduction
Nadja Banziger is a prominent inventor based in Schlieren, Switzerland. She has made significant contributions to the field of medical biotechnology, particularly in the development of innovative therapeutic solutions. Her work focuses on the inhibition of glycosylated IL-17A, a critical factor in various inflammatory diseases.
Latest Patents
Nadja Banziger holds a patent for "IL-17A binding molecules and medical uses thereof." This invention relates to a polypeptide that inhibits the activity of glycosylated IL-17A. The polypeptide comprises or consists of an amino acid sequence selected from a specific group, with certain positions allowing for variability. The invention also encompasses fusion constructs, compositions, and medical uses that include this polypeptide.
Career Highlights
Banziger is associated with Covagen AG, a company known for its innovative approaches in the field of biopharmaceuticals. Her work has been instrumental in advancing therapeutic options for patients suffering from autoimmune diseases. With her expertise, she has contributed to the development of novel treatments that target specific biological pathways.
Collaborations
Nadja has collaborated with notable colleagues, including Michela Sillacci Melkko and Richard Woods. These partnerships have fostered a collaborative environment that enhances research and development efforts in the biotechnology sector.
Conclusion
Nadja Banziger's contributions to medical biotechnology exemplify the impact of innovative thinking in addressing complex health challenges. Her patent on IL-17A binding molecules showcases her commitment to advancing therapeutic solutions. Through her work at Covagen AG and collaborations with esteemed colleagues, she continues to make strides in the field.